Side-by-side studies of diflapolin with the “FLAP benchmark inhibitor” MK88640 revealed comparable potencies for inhibition of 5-LOX product biosynthesis in human leukocytes in vitro, and about equal effectiveness in suppression of LT formation and inflammatory properties in vivo using murine zymosan-induced peritonitis models. This evidence concerns the gene ALOX5 and peritonitis.